Overall Survival with Amivantamab-Lazertinib in &lt;i&gt;EGFR&lt;/i&gt;-Mutated Advanced NSCLC
Janssen Research & Development, LLC
James Chih-Hsin Yang; Shun Lu; Hidetoshi Hayashi; Enriqueta Felip; Alexander I Spira; Nicolas Girard; Yu Jung Kim; Se-Hoon Lee; Yurii Ostapenko; Pongwut Danchaivijitr; Baogang Liu; Adlinda Alip; Ernesto Korbenfeld; Josiane Mourão Dias; Benjamin Besse; Antonio Passaro; Ki-Hyeong Lee; Hailin Xiong; Soon-Hin How; Ying Cheng; Gee-Chen Chang; Hiroshige Yoshioka; Michael Thomas; Danny Nguyen; Sai-Hong Ignatius Ou; Sanjay Mukhedkar; Kumar Prabhash; Manolo D'Arcangelo; Jorge Alatorre-Alexander; Juan Carlos Vázquez Limón; Sara Alves; Daniil Stroyakovskiy; Marina Peregudova; Mehmet Ali Nahit Şendur; Ozan Yazici; Raffaele Califano; Vanesa Gutiérrez Calderón; Filippo de Marinis; Sang-We Kim; Shirish M Gadgeel; Scott Owen; John Xie; Tao Sun; Jaydeep Mehta; Raja Venkatasubramanian; Mariah Ennis; Elizabeth Fennema; Mahesh Daksh; Amy Roshak; Julie Man; Roland E Knoblauch; Joshua M Bauml; Mahadi Baig; Sujay Shah; Seema Sethi; Byoung Chul Cho; MARIPOSA Investigators